PROGRAM CHAIRS & FACULTY PRESENTERS
Erica Mayer, MD, MPH
Director, Clinical Research
Dana-Farber Cancer Institute
Associate Professor of Medicine
Harvard Medical School
Boston, MA
Geoffrey C. Wall, PharmD, FCCP, BCPS
John R. Ellis Distinguished Chair of Pharmacy Practice
Professor of Clinical Sciences
Director, Drake Drug Information Center
Drake University College of Pharmacy and Health Sciences
Internal Medicine Clinical Pharmacist
Iowa Methodist Medical Center
Des Moines, IA
PROGRAM OVERVIEW
This Immersive Simulation experience focuses on strategies to overcome resistance to endocrine therapy in early HR+/HER2- breast cancer. Through the Simulation Center activity, healthcare practitioners will develop a plan to help patients consistently and tolerably use oral anti-cancer medications for HR+/HER2- breast cancer. The program will analyze clinical trial data on CDK4/6 inhibitors in early HR+/HER2- breast cancer to optimize monitoring and managing treatment-associated adverse events. Additionally, healthcare practitioners will develop strategies to support patients in their adherence and persistence with agreed-upon treatment plan for HR+/HER2- early breast cancer.
TARGET AUDIENCE
This CME initiative is designed to meet the educational needs of medical oncologists, oncology nurses, pharmacists, nurse practitioners, physician assistants, and other oncology healthcare team providers involved in the treatment of patients with hormone receptor-positive, HER2-negative breast cancer.
LEARNING OBJECTIVES
Upon the completion of this program, attendees should be able to:
- Formulate a plan to support a patient’s consistent, chronic, and tolerable use of oral anti-cancer medications for HR+/HER2-negative breast cancer
- Critically analyze CDK 4/6 inhibitor clinical trials data in early HR+/HER2-negative breast cancer to optimize the monitoring and management of treatment-associated adverse events
- Develop strategies to support the patient’s adherence and persistence with agreed upon treatment for HR+/HER2-negative early breast cancer
ACCREDITATION STATEMENT
Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. This CME activity was planned and produced in accordance with the ACCME Essentials.
PHYSICIAN CREDIT DESIGNATION STATEMENT
Med Learning Group designates this enduring activity for a maximum of 0.75 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.
JOINT ACCREDITATION STATEMENT
In support of improving patient care, this activity has been planned and implemented by Amedco LLC and Med Learning Group. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
NURSES (ANCC) CREDIT DESIGNATION
Amedco LLC designates this activity for a maximum of 0.75 ANCC contact hours.
PHARMACISTS AND PHARMACY TECHNICIANS (ACPE) CREDIT DESIGNATION
Amedco LLC designates this activity for a maximum of 0.75 knowledge-based CPE contact hours.
UAN(s): JA4008163-9999-24-013-H01-P / JA4008163-9999-24-013-H01-T
NOTE to Pharmacists: The only official Statement of Credit is the one you pull from CPE Monitor. You must request your certificate within 45 days of your participation in the activity to meet the deadline for submission to CPE Monitor. Credits are generally reported during the first week of each month for those who claimed during the month prior.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Integrity and Independence in Accredited Continuing Education, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF RELEVANT FINANCIAL RELATIONSHIPS
| Faculty Member | Disclosures |
| Erica Mayer, MD | Consulting Fees: AstraZeneca, Lilly, Novartis |
| Geoffrey C. Wall, PharmD, FCCP, BCPS | Speakers Bureau: Janssen |
All relevant financial relationships have been mitigated.
CME Content Review
The content of this activity was independently peer reviewed.
The reviewer of this activity has nothing to disclose.
CNE Content Review
The content of this activity was peer reviewed by a nurse reviewer.
The reviewer of this activity has nothing to disclose.
Staff Planners and Managers
The staff, planners, and managers reported the following financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CME/CE activity:
- Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to disclose.
- Christina Gallo, SVP, Educational Development for Med Learning Group, has nothing to disclose.
- Lauren Welch, MA, VP, Accreditation and Outcomes for Med Learning Group, has nothing to disclose.
- Nicole Longo, DO, FACOI, VP Med/Sci Services & Learner Engagement for Med Learning Group, has nothing to disclose.
- Lisa Kuhns, PhD, Medical Director for Med Learning Group, has nothing to disclose.
- Jessica McMullen, MPH, Senior Program Manager for Med Learning Group, has nothing to disclose.
- Laura Aibara, Program Coordinator, for Med Learning Group, has nothing to disclose.
- Daniel DaSilva, Accreditation and Outcomes Coordinator, has nothing to disclose.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States. During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.
METHOD OF PARTICIPATION
There are no fees for participating and receiving CE credit for this activity. In order to obtain your certificate for the mentioned accreditation, participants need to successfully complete the associated pre/post activities and evaluation. Your certificate will be provided as a downloadable file.
DISCLAIMER
Med Learning Group makes every effort to develop CME activities that are science based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making expertise before applying any information, whether provided here or by others, for any professional use.
For CME questions, please contact Med Learning Group at [email protected]
Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/
AMERICANS WITH DISABILITIES ACT
Event staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at [email protected]
RELEASED DATE: January 30, 2024
EXPIRATION DATE: January 30, 2025
Copyright © 2024 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.
